Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MRA-ACE: Spironolactone in Diabetic Nephropathy
NCT03502031Phase 4Unknown
- Start
- Oct 2018
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of spironolactone in diabetic glomerulosclerosis (2 arms). Primary endpoint: Urinary Protein to Creatinine Ratio at 24 months. Status: unknown.
02
Drugs
spironolactone
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on NCT03502031.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03502031.